- Titre
- Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma
- Créateurs - sans rôle
- Jorge J Castillo - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAThomas Guerrero-Garcia - Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, USAFrancesco Baldini - National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, ItalyEmmanuelle Tchernonog - Department of Haematology, CHU Montpellier, Montpellier, FranceGuillaume Cartron - Department of Haematology, CHU Montpellier, Montpellier, FranceSlavisa Ninkovic - Department of Haematology, UCLH London, London, UKKate Cwynarski - Department of Haematology, UCLH London, London, UKDaan Dierickx - Department of Haematology, University Hospitals Leuven, Leuven, BelgiumThomas Tousseyn - Department of Haematology, University Hospitals Leuven, Leuven, BelgiumFrederick Lansigan - Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USAYevgeny Linnik - Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USARenzo Mogollon - Department of Medicine, Universidad San Martin de Porres, Lima, PeruJose-Tomás Navarro - Catalan Institute of Oncology, German Trias I Pujol Hospital, Badalona, SpainAdam J Olszewski - Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USAJohn L Reagan - Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USAPasquale Fedele - Monash Haematology, Monash Medical Centre, Monash University, Clayton, AustraliaMichael Gilbertson - Monash Haematology, Monash Medical Centre, Monash University, Clayton, AustraliaGeorge Grigoriadis - Monash Haematology, Monash Medical Centre, Monash University, Clayton, AustraliaMichele Bibas - National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
- Détails de publication
- British journal of haematology, Vol.184(4), pp.679-682
- Identifiants
- 99139750409311
- Unité académique
- Institut de Génétique Moléculaire de Montpellier - IGMM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma
British journal of haematology, Vol.184(4), pp.679-682
02/2019
PMID: 29527667
Indicateurs
1 Consultations de la notice